v3.25.1
Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) - USD ($)
Preferred Stock
Series A
Common Stock
Additional Paid-in Capital
Treasury Stock
Accumulated Deficit
Accumulated Other Comprehensive Income
Due from Shareholders
Total Onconetix Equity (Deficit)
Non- controlling Equity (Deficit)
Total
Balance at Dec. 31, 2022 $ 4 $ 42,331,308 $ (566,810) $ (19,376,500)   $ 22,388,002 $ 22,388,002
Balance (in Shares) at Dec. 31, 2022 393,107                
Balance (in Shares) at Dec. 31, 2022       (11,493)            
Issuance of common stock from exercise of preferred investment options   2,272,838     2,272,838 2,272,838
Issuance of common stock from exercise of preferred investment options (in Shares)   62,155                
Issuance of warrants for settlement of contingent warrants   129,184     129,184 129,184
Issuance of Series A Preferred Stock 3,490,000     3,490,000 3,490,000
Issuance of Series A Preferred Stock (in Shares) 3,000                  
Issuance of common stock and Series B Preferred Stock in connection with PMX Transaction   $ 2 875,482     875,484 875,484
Issuance of common stock and Series B Preferred Stock in connection with PMX Transaction (in Shares)   91,885                
Assumption of stock-based compensation plan awards in connection with PMX Transaction       7,006,504 7,006,504
Exercise of stock options   459     459 459
Exercise of stock options (in Shares)   1,148                
Exercise of pre-funded warrants      
Exercise of pre-funded warrants (in Shares)   16,166                
Issuance of restricted stock      
Issuance of restricted stock (in Shares)   12,823                
Stock-based compensation   329,760     329,760 329,760
Purchase of treasury shares   $ (58,981)   (58,981) (58,981)
Purchase of treasury shares (in Shares)       (1,441)            
Forfeitures of restricted stock      
Forfeitures of restricted stock (in Shares)   (6,251)                
Foreign currency translation adjustment     2,374,957   2,374,957 2,374,957
Changes in pension benefit obligation     5,963   5,963 5,963
Net loss     (37,409,694)   (37,409,694) (37,409,694)
Balance at Dec. 31, 2023 $ 6 49,429,031 $ (625,791) (56,786,194) 2,380,920 (5,602,028) 7,006,504 $ 1,404,476
Balance (in Shares) at Dec. 31, 2023 3,000 571,033                
Balance (in Shares) at Dec. 31, 2023       (12,934)           12,934
Issuance of common stock and warrants from exercise of preferred investment options, net of issuance costs   $ 2 765,027   765,029 $ 765,029
Issuance of common stock and warrants from exercise of preferred investment options, net of issuance costs (in Shares)   186,466                
Grant and immediate exercise of warrants   $ 2 6,153   6,155 6,155
Grant and immediate exercise of warrants (in Shares)   154,027                
Issuance of shares in connection with related party subscription agreement   $ 5 5,134,242   5,134,247 5,134,247
Issuance of shares in connection with related party subscription agreement (in Shares)   513,424                
Conversion of Series A Preferred Stock to common stock $ 1 (1)  
Conversion of Series A Preferred Stock to common stock (in Shares) (3,000) 142,749                
Conversion of Series B Preferred Stock to common stock   $ 67 64,236,018   64,236,085 64,236,085
Conversion of Series B Preferred Stock to common stock (in Shares)   6,741,820                
Exercise of stock options   163   163 163
Exercise of stock options (in Shares)   406                
Stock-based compensation   260,406   260,406 178,247 438,653
Issuance of restricted common stock    
Issuance of restricted common stock (in Shares)   16,668                
Forfeitures of restricted stock    
Forfeitures of restricted stock (in Shares)   (312)                
Cash in lieu of shares   (719)   (719) (719)
Cash in lieu of shares (in Shares)   (227)                
Foreign currency translation adjustment     (5,342,327) (5,342,327) (5,342,327)
Issuance of common stock in connection with the ELOC   $ 28 935,562   (250,308) 685,282 685,282
Issuance of common stock in connection with the ELOC (in Shares)   2,757,933                
Issuance of restricted common stock in exchange in exchange for options   $ 7 7,184,744   7,184,751 (7,184,751)
Issuance of restricted common stock in exchange in exchange for options (in Shares)   683,456                
Adjustment to redeemable Series C preferred Stock   (125,000)   (206,404) (331,404) (331,404)
Changes in pension benefit obligation     238,010 238,010 238,010
Net loss     (58,691,023) (58,691,023) (58,691,023)
Balance at Dec. 31, 2024 $ 118 $ 127,825,626 $ (625,791) $ (115,683,621) $ (2,723,397) $ (250,308) $ 8,542,627 $ 8,542,627
Balance (in Shares) at Dec. 31, 2024 11,767,443                
Balance (in Shares) at Dec. 31, 2024       (12,934)           12,934